Trophoblast cell-surface antigen 2 (TROP2) is overexpressed in advanced or metastatic urothelial cancer (UC), representing a promising therapeutic target. Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed antibody-drug conjugate with a unique, bifunctional linker that maximizes payload delivery to tumor cells. We present preliminary results for sac-TMT monotherapy from cohort 9 of the phase 1/2 2870-001/KL264-01 study in participants with advanced or…
Sacituzumab Tirumotecan in Participants With Advanced or Metastatic Urothelial Carcinoma and Disease Progression after Chemotherapy and Immune Checkpoint Inhibitors
Annals of Oncology | | Y. Zhu, S. Jiang, Y. Shi, S. Wang, F. Yuan, F. Zhou, K. Jiang, X. Zhang, L. Seneviratne, G. Yu, M. Zhang, T. Liu, X. Li, X. Chen, X. Wang, S. Zhang, Y. Liu, Y. Ge, M. Chen, G. Blumenthal, O. Akala, Y. Li, X. Li, J. Ge, D. Ye
Topics: bladder-cancer, cervical-cancer, immunotherapy, targeted-therapy, chemotherapy, clinical-trials, new-technology, research